TY - JOUR
T1 - Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl
AU - Martignoni, E.
AU - Bono, G.
AU - Blandini, F.
AU - Sinforiani, E.
AU - Merlo, P.
AU - Nappi, G.
PY - 1991/3
Y1 - 1991/3
N2 - An impairment of the monoaminergic systems has frequently been reported for Alzheimer's disease (AD) as well as an overactivity of cerebral monoamineoxidase B (MAO-B). L-deprenyl (LD), a selective and irreversible MAO-B inhibitor, has recently been proposed for the treatment of AD. The cerebrospinal fluid (CSF) levels of norepinephrine (NE), epinephrine (E), dopamine (DA), 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA) were studied in 14 patients suffering from dementia of Alzheimer type (DAT) and in 14 controls. A three-month double-blind study comparing LD with placebo was carried out, in the DAT group, and the influence of the treatment on neurotransmitter levels and cognitive performance was evaluated. The basal study revealed a significant reduction in CSF NE and HVA levels in DAT patients when compared with controls; the treatment with LD determined a significant decrease in HVA levels only and, as to neuropsychological investigation, a global amelioration of cognitive performances.
AB - An impairment of the monoaminergic systems has frequently been reported for Alzheimer's disease (AD) as well as an overactivity of cerebral monoamineoxidase B (MAO-B). L-deprenyl (LD), a selective and irreversible MAO-B inhibitor, has recently been proposed for the treatment of AD. The cerebrospinal fluid (CSF) levels of norepinephrine (NE), epinephrine (E), dopamine (DA), 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA) were studied in 14 patients suffering from dementia of Alzheimer type (DAT) and in 14 controls. A three-month double-blind study comparing LD with placebo was carried out, in the DAT group, and the influence of the treatment on neurotransmitter levels and cognitive performance was evaluated. The basal study revealed a significant reduction in CSF NE and HVA levels in DAT patients when compared with controls; the treatment with LD determined a significant decrease in HVA levels only and, as to neuropsychological investigation, a global amelioration of cognitive performances.
KW - cerebrospinal fluid
KW - dementia of Alzheimer type
KW - L-deprenyl
KW - Monoamines
UR - http://www.scopus.com/inward/record.url?scp=0025909805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025909805&partnerID=8YFLogxK
U2 - 10.1007/BF02251133
DO - 10.1007/BF02251133
M3 - Article
C2 - 1712206
AN - SCOPUS:0025909805
VL - 3
SP - 15
EP - 25
JO - Journal of Neuro-Visceral Relations
JF - Journal of Neuro-Visceral Relations
SN - 0375-9245
IS - 1
ER -